Showing 1791-1800 of 5910 results for "".
- Eye Love Rock ‘N Roll Event Headlining Holland Foundation Fundraiser at ASCRShttps://modernod.com/news/eye-love-rock-n-roll-event-headlining-holland-foundation-fundraiser-at-ascrs/2481454/A band of ophthalmologists and industry professionals will perform during the Holland Foundation of Site Restoration’s fundraiser, “Eye Love Rock ‘N Roll,” during the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in San Diego. Th
- Zeiss Opens New High-Tech Center in San Francisco Bay Areahttps://modernod.com/news/zeiss-opens-new-high-tech-center-in-san-francisco-bay-area/2479038/Zeiss has completed construction of its new R&D, production, sales and customer service site in the San Francisco Bay Area. Bringing together hundreds of Zeiss employees and key functions under one roof, represents a major milestone in the company’s international innovation and growth
- Adverum Biotechnologies Announces New GMP Gene Therapy Manufacturing Facilityhttps://modernod.com/news/adverum-biotechnologies-announces-new-gmp-gene-therapy-manufacturing-facility/2478734/Adverum Biotechnologies announced plans for a new Good Manufacturing Practices facility in Durham, North Carolina. Adverum will invest over $80 million in the 174,000-square-foot facility, located in Research Triangle Park (RTP). The site will include four 1,000-liter bioreactors, with space for
- Nicox Reports on Enrollment Progress in Mont Blanc Phase 3 Clinical Trial in Glaucomahttps://modernod.com/news/nicox-reports-on-enrollment-progress-in-mont-blanc-phase-3-clinical-trial-in-glaucoma/2478024/Nicox SA announced that over 40 sites have been initiated in the first month of the phase 3 Mont Blanc trial, evaluating NCX 470 for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. NCX 470 is the company’s novel, second-generation nitric oxide (NO)-donating bimato
- Sensible Medical Announces Partnership Aimed at Restoring Confidence for Safe Surgery During COVID-19https://modernod.com/news/sensible-medical-announces-partnership-aimed-at-restoring-confidence-for-safe-surgery-during-covid-19/2478015/Sensible Medical has announced exclusive distribution rights for the United States and Canada of Toul Meditech’s Operio Mobile and SteriStay Clean Air Zone Systems for surgery and special procedures. The ultraclean H14 filtration system creates laminar airflow at the surgical site, protec
- Novartis Asks Workers in Europe, US and Canada to Work From Homehttps://modernod.com/news/novartis-asks-workers-in-europe-us-and-canada-to-work-from-home/2477394/Due to the COVID-19 outbreak, Novartis released a statement requesting that effective today, its associates within the United States, Europe, and Canada to work from home, with the exception of those working in laboratories, manufacturing sites, and in the field. The measure is valid for 3
- Topcon Announces the Release of Harmony Into the EMEA Regionhttps://modernod.com/news/topcon-announces-the-release-of-harmony-into-the-emea-region/2476835/Topcon has announced the release and clearance of the Topcon Harmony, a class II medical diagnostic software, into the EMEA market. Topcon Harmony is a responsive browser-based software application for on-site or cloud-hosted environments that allows practitioners to connect all of their diagnost
- Study: Glaukos iStent inject Implantation with Concomitant Cataract Surgery Provides Sustained Reduction in IOP and Medication Burdenhttps://modernod.com/news/study-glaukos-istent-inject-implantation-with-concomitant-cataract-surgery-provides-sustained-reduction-in-iop-and-medication-burden/2479620/Glaukos announced that a single-site international study of glaucoma subjects recently published in Ophthalmology and Therapy showed that the iStent inject Trabecular Micro-Bypass System, combined with cataract surgery, achieved a 37% reduction in mean IOP to 14.3 mmHg after 3 years of f
- Ora Names Gustavo De Moraes, MD, PHD, Chief Medical Officerhttps://modernod.com/news/ora-names-gustavo-de-moraes-md-phd-chief-medical-officer/2480622/Ora announced that distinguished op
- FDA Grants DeNovo Classification to Balance Ophthalmics' FYSX Ocular Pressure Adjusting Pumphttps://modernod.com/news/fda-grants-denovo-classification-to-balance-ophthalmics-fysxtm-ocular-pressure-adjusting-pump/2482333/Balance Ophthalmics announced that the FDA has granted DeNovo Classification of the FYSX Ocular Pressure Adjusting Pump, a new category of treatment for patients with normal tension glaucoma (NTG) and open-angle glaucoma (OAG) with IOP ≤ 21 mmHg. “The FDA classif